Exclusive: Co-Diagnostics reaches regulatory milestone for PCR respiratory test platform

Co-Diagnostics Inc. CODX on Wednesday said it completed clinical and analytical performance studies for the Co-Dx PCR Flu A/B ...
The American Journal of Managed Care

Two-Step Testing Helps Predict and Treat Recurrent C difficile Infection

This study explores the effectiveness of toxin testing in predicting Clostridioides difficile infection (CDI) outcomes, revealing that patients with negative toxin results were less likely to ...
Nasdaq

Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Nasdaq

Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities

SALT LAKE CITY, June 2, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Morningstar

Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies

SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...